{
  "id": 85303,
  "title": "Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny",
  "url": "https://urgent.news/2026/08/03/chinese-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid-85303",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-03T12:30:14.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/business/banking-finance/article/3362817/chinese-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid-us-scrutiny"
  },
  "original_language": "en",
  "account": null,
  "summary": "Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, posted net income that smashed market expectations in the first half of the year amid strong demand tied to weight-loss and diabetes drugs, as well as gains in its US business. Interim net profit attributable to the owners of the Shanghai-based drug contractor advanced 33.7 per cent to 11.08 billion yuan (US$1.64 billion)…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "SCMP Business",
        "title": "Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny",
        "url": "https://urgent.news/2026/08/03/chinese-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid",
        "published": "2026-08-03T12:30:14.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}